Jpmorgan Chase & CO Terns Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 153,080 shares of TERN stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

153,080

Previous 421,637 63.69%

Holding current value

$1.09 Million

Previous $2.77 Million 62.31%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$4.54 - $8.2 $1.22 Million - $2.2 Million	-268,557 Reduced 63.69%	153,080 $1.04 Million
Q1 2024 May 10, 2024	BUY	$4.86 - $8.19 $988,698 - $1.67 Million	203,436 Added 93.23%	421,637 $2.77 Million
Q4 2023 Feb 12, 2024	SELL	$3.37 - $6.86 $218,827 - $445,447	-64,934 Reduced 22.93%	218,201 $1.42 Million
Q3 2023 Nov 14, 2023	SELL	$4.7 - $8.55 $462,856 - $842,004	-98,480 Reduced 25.81%	283,135 $1.42 Million
Q2 2023 Aug 11, 2023	SELL	$7.35 - $13.29 $1.84 Million - $3.32 Million	-250,131 Reduced 39.59%	381,615 $3.34 Million
Q1 2023 May 11, 2023	SELL	$7.91 - $12.0 $4.55 Million - $6.9 Million	-575,405 Reduced 47.67%	631,746 $7.48 Million
Q4 2022 Feb 13, 2023	BUY	$4.62 - $10.18 $1.33 Million - $2.93 Million	288,109 Added 31.35%	1,207,151 $12.3 Million
Q3 2022 Nov 14, 2022	BUY	$1.87 - $6.42 $1.72 Million - $5.89 Million	918,079 Added 95335.31%	919,042 $5.41 Million
Q2 2022 Aug 11, 2022	SELL	$1.5 - $3.0 $12,606 - $25,212	-8,404 Reduced 89.72%	963 $2,000
Q1 2022 May 11, 2022	BUY	$2.83 - $6.7 $5,442 - $12,884	1,923 Added 25.83%	9,367 $28,000
Q4 2021 Feb 10, 2022	BUY	$5.65 - $10.73 $12,373 - $23,498	2,190 Added 41.68%	7,444 $52,000
Q3 2021 Nov 12, 2021	BUY	$7.22 - $13.46 $37,933 - $70,718	5,254 New	5,254 $55,000

Others Institutions Holding TERN

# of Institutions

136

Shares Held

63.6M

Call Options Held

413K

Put Options Held

106K

View Full List

About Terns Pharmaceuticals, Inc.

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $267M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

More about TERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Terns Pharmaceuticals, Inc. Transaction History